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Manuscript Text: 
The global burden of hepatitis C infection and the emergence of effective therapies 
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An estimated 80-150 million people are infected with hepatitis C infection (HCV) worldwide, with the 
highest prevalence rates in low- and medium-income countries of Africa and Asia. HCV-related liver 
disease mortality is estimated to be half a million per annum.1,2  
Chronic HCV treatment was interferon-based for two decades, with the addition of ribavirin (RBV),3 
pegylated-interferon (PEG-IFN)4 and initial protease inhibitor direct acting antiviral (DAA) therapies 
(telaprevir, boceprevir)5,6  subsequently providing stepwise improvements in the rate of sustained 
virological response (SVR). Despite these improvements, interferon-containing HCV therapy uptake 
remained low in most countries, ranging from <1% to a maximum of 5% of people with chronic HCV 
initiating therapy each year.7 Fortunately, recent years have seen a revolution in HCV therapeutic 
development, with the advent of interferon-free DAA therapies, which disrupt replication through 
inhibition of HCV protease, polymerase and NS5A function.8 Simple (single daily dosing oral regimens), 
highly tolerable, short-duration (8-24 weeks) regimens with extremely high efficacy (cure rates above 
95%) have been developed and registered internationally. Used in various combinations depending on 
HCV genotypes and previous treatment exposure, these include:  sofosbuvir/ledipasvir ,9-11 
paritaprevir/ritonavir/ombitasvir/dasabavir/+/-ribavirin ,12-14 sofosbuvir/daclatasvir,15,16 
elbasvir/grazoprevir,17,18 and sofosbuvir/velpatasvir.  
There is clear evidence that HCV cure impacts HCV-related liver disease and hepatocellular carcinoma 
(HCC) risk.19 Early treatment may have greater benefit. Furthermore, as a result of the high efficacy and 
tolerance, and ease of delivery of these medications, HCV treatment as prevention is being explored in 
some countries, particularly treating high prevalence populations, such as people who inject drugs and 
incarcerated populations.20 The broad implementation of these therapeutic regimens has the potential 
to dramatically impact HCV-related disease burden globally. Indeed, new HCV treatments have been 
deemed so important that some (sofosbuvir, daclatasvir) were added to the 2015 WHO Essential 
Medicines List along with a number of their combinations.21  
Standard channels for accessing new therapies for HCV 
High drug pricing for interferon-free DAA regimens (up to USD93,000 per 12 week course) has limited 
broad implementation in the vast majority of settings, with restrictions based on liver disease stage 
generally introduced to reduce budget impact.22 Other restrictions, including those based on ongoing 
drug and alcohol use, have further limited access in many settings, particularly within the United 
States.22 Even in high income countries, there is considerable diversity in access to and pricing of new 
HCV therapies.  
In the United Kingdom, spending on HCV treatment increased almost 5-fold between 2014 and 2015 to 
£190 million. It has been estimated that it would cost over £4 billion to treat the estimated 214,000 
people with chronic HCV in the UK at a cost of £20,000, so access has generally been restricted to those 
with advanced liver disease.23 The Australian government has allocated AUD1 billion to the 
Pharmaceutical Benefits Scheme to fund HCV DAA therapies for the next 5 years, with no restrictions 
based on liver disease stage. This is a volume-based pricing deal between the Government and 
Pharmaceutical companies.24 While details are not publicly available, it is understood that this deal is 
expected to provide treatment for approximately 60,000 individuals. However, there is also a risk-
sharing arrangement in place, so that if more individuals are treated then the cost would be borne by 
the pharmaceutical companies rather than the by Government which would mean the cost-per-
treatment would fall. In the initial five months of the DAA program (March to July 2016), an estimated 
26,360 patients initiated therapy, with possibly 40,000 to be treated in 2016 representing 17% of the 
total chronic HCV infection population in Australia.25  
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Patients who live in countries that do not have universal government funding schemes, or who do not fit 
specific criteria for subsidization, must wait until these medicines are funded by their public or private 
insurers, or find other avenues to access medicines such as through clinical trials, industry  access 
schemes or personal fundraising. All of these means of accessing medicines are, however, ad hoc and 
many patients miss out. This not only affects the individuals concerned, but also greatly limits the public 
health impact of new HCV therapies.26 
Personal importation of hepatitis C therapies 
In some lower income countries, voluntary licenses have been issued, which allow generic versions of 
patented medicines to be manufactured, providing greater access to new HCV medicines. In India 11 
generic companies signed voluntary licenses with Gilead for sofosbuvir and ledipasvir/sofosbuvir, and 
are permitted to supply these medicines to more than 100 low- and middle-income countries around 
the world.28 However, this agreement explicitly prohibits supply to a number of middle- and high-
income countries. The resulting discrepancy between prices in high-income countries and those in lower 
income countries can be taken advantage of by patients in wealthier countries. Patients may, for 
example, travel to countries where medicines are less expensive (“medical tourism”). Alternatively, they 
can import less expensive versions of the medicines they need.  
Australia, for example, has legislation permitting individuals to import up to 12 weeks of unlicensed 
medicines at their own risk. While a prescription and consent is needed, no further regulatory oversight 
is required for most classes of medicines. Significantly for patients with HCV, a 12 week supply of 
medicines is generally sufficient for HCV treatment. 
Prior to the commencement of the Australian government funded HCV treatment program in March 
2016, an estimated 1400 Australian patients were treated with the assistance of FixHepC, a web-based 
platform for the importation of HCV therapies.28 Through importation and compounding of the active 
pharmaceutical ingredients (APIs) for sofosbuvir, ledipasvir and daclatasvir from India, patients were 
able to access a course of 12 weeks of therapy for AU$1500-$2000—a fraction of the market price for 
these treatments. More recently FixHepC has sourced these medicines from generic companies in India 
and Bangladesh. 
Importation schemes were supported by professional bodies such as Australasian Society of HIV, Viral 
Hepatitis and Sexual Health Medicine (ASHM).29 The ASHM released a position statement in October 
2015, which outlined their support for the new treatments, making recommendations about specific 
antivirals and the methods by which they may be procured - including purchasing these medicines from 
overseas or over the internet. In addition to having obvious appeal to people with HCV, importation 
schemes may play an indirect role in securing greater discounts within government and large payer-
funded HCV treatment programs. 
This raises the question, why are large scale personal importation schemes not more widely 
implemented? 
While importation per se is generally legal, in some settings, there are regulations that preclude the 
importation and/or prescribing of cheaper imported medicines.  The United States, like Australia, 
permits personal importation, but officially excludes importing medicines from overseas that are 
cheaper than those that are available locally.30 In some countries, while personal importation may be 
permitted, there may be limits regarding what medicines physicians can prescribe. For instance, in 
Europe, prescribing off-label or unlicensed medicines on the basis of cost-saving alone is illegal, and the 
UK’s General Medical Council supports this position.31 How well this is, and can be, policed is another 
matter. The FixHepC website provides access to DAA therapy to patients in the United Kingdom, 
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overcoming this barrier by providing patients an online consultation with an Australian doctor, who 
provides prescriptions from Australia.  
While safety is no doubt a major reason why many hold reservations about personal importations of 
medicines, it is also likely that economic factors and political pressure plays a part. For example, when 
Thailand issued a compulsory license for some cancer medicines, the United States responded by 
downgrading their trading status.32 When France utilized its Temporary Recommendations for Use to 
support the off-label use of Avastin for aged-related macular degeneration at a fraction of the price of 
the registered alternative, they faced stiff opposition from the European pharmaceutical lobby.33 While 
these cases are not instances of personal importation, they demonstrate that even governments aiming 
to provide access to affordable medicines for their citizens in good-will can face stiff challenges from 
industry or foreign governments. 
There are also barriers to organized forms of personal importation, such as FixHepC. For example, in 
Australia there appear to be unresolved legal, political, and operational complexities when it comes to 
large scale forms of importation, where physicians, exporters, prescribers and compounding 
pharmacists collude to treat patients with cheaper, unlicensed versions of a medicine. This is no doubt 
in part due to legitimate concerns about the purity of APIs, and the fact there is no guarantee that the 
manufacturing process meets national standards. Indeed, Australia’s Therapeutics Goods Adminstration 
recently ordered the FixHepC website to cease ‘advertising prescription-only medicines’, and in 
response its operations have subsequently moved to Myanmar.34 This order was, however, dated to 
May 2016, after Australia had already started subsidising HCV medicines for the general public, and 
therefore would have had minimal impact on access.  
Despite the reservations that many countries seem to have about personal importation schemes, the 
Australian experience suggests that, if done well, organized importation of unlicensed HCV medicines do 
not expose patients to unnecessary risks and provides access to effective therapies. In the recent 
Australian REDEMPTION study (n=412) using DAA HCV therapy accessed through the FixHepC website, 
outcomes were equivalent to those using branded treatments. The quality of APIs were evaluated using 
liquid chromatography, nuclear magnetic resonance and mass spectroscopy. The interim week 12 
sustained virological response (SVR) for genotype 1 HCV was 95% using imported sofosbuvir and 
ledipasvir or imported sofosbuvir and daclatasvir. The cohort included 28% of individuals with cirrhosis. 
Across all genotypes the SVR was 94% revealing equivalent clearance rates at 1/100th the cost.35  
Whether or not countries choose to support personal importation schemes for legal, economic and 
practical reasons, the fact is that there is demand for such schemes, and this demand is not specific to 
HCV therapy. A case in point is the ‘I Want PreEP Now’ website which provides recommendations and 
guidance to UK residents about how and where to buy generic versions of unsubsidised medicines for 
pre-exposure prophylaxis for HIV. While the brand name medicine is available through private clinics at 
a cost of £400 for 30 pills, generic products are available through the website at a tenth of the price.36 
And in the US state of Maine, laws passed in 2013 permitted residents to purchase cheaper medicines 
online from countries deemed to have equivalent or greater licensing regulations, until this state law 
was overturned in 2015 as it was deemed to compromise federal regulation.37  This tension between 
what people seem to want, and what countries are willing to support, suggests that there must be 
strong moral and socio-political arguments both for and against personal importation.  
Moral and socio-political arguments for and against personal importation  
Against such schemes, it could be argued that patients in high-income countries should not have access 
to cheaper medicines available in low income countries because price discrepancies are legitimate 
responses to the ability of different markets to pay for medicines. Importing medicines from low-income 
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countries may compromise the discounting schemes provided to these countries if the practice becomes 
too widespread. This could mean that the most vulnerable patients may suffer as pharmaceutical 
companies refuse to discount prices to protect their investments, or refuse to contribute to schemes 
such as the Medicines Patent Pool which aims to make medicines more accessible in low and middle-
income countries (e.g. Bristol-Myers Squibb has added daclatasvir to this pool).38 It could also be argued 
that these practices undermine intellectual property laws and threaten current and future investment in 
drug development, which would have negative long-term consequences worldwide.  
On the other hand, the fact that medicines can be sold at massive discounts in many parts of the world 
(and presumably not at a loss) calls into question the legitimacy of prices charged in many high-income 
countries – for instance in Egypt, sofosbuvir sells at a 99% discount to the US price,39 and it has been 
estimated that HCV treatments could be manufactured for less than US$200 per patient.40 While the 
issue of drug pricing is complex, and prices cannot be determined solely on the basis of manufacturing 
costs, concerns about the legitimacy of HCV drug prices have been buttressed by the results of a recent 
investigation of Sovaldi’s pricing in the United States. The resulting US Senate Report concluded that 
Gilead aimed to set high pricing precedents ‘in early launch markets’ and to set a high baseline price for 
successor products.41 In addition it found that the price of Sovaldi was aimed at maximizing revenue 
based on expectations of how payers would react to the price, rather than being connected to 
underlying costs of development, or investment returns. The Attorney-General of one US state has 
threatened to take legal action against Gilead for the pricing of its medicines, arguing that it ‘may 
constitute an unfair trade practice’.42 In this regard it is worth noting that between 2013 and 2015, 
Gilead’s sales revenue for Solvaldi and Harvoni was more than $31 billion, with $19 billion of these 
products sold in 2015 alone.43,44 
Balancing compassion and industry interests 
It is important to keep in mind that the practice of personal importation is driven by the very same 
imperative that allows companies to charge high prices for life-saving medicines – hope. When hope 
fades because the cure is too expensive, no one can blame patients for seeking other avenues to access 
treatments. While it is not an ideal solution, and governments do have options available to them,27 the 
case of HCV shows that under certain circumstances, personal importation can work as a stop-gap 
measure until better and longer term solutions are found. We also need to keep in mind that the 
problem is a global one—while personal importation may provide hope to people in relatively wealthy 
countries, universal access will not be achieved in this way. While the cost of manufacturing DAAs is 
rapidly declining, raising the prospect that more people who need these treatments will be able to 
access them,45 there are many other commercial forces at play, which mean that prices will not 
necessarily fall according to standard market logics. 
The generic importation of HCV medication thus highlights the problems of drug cost, regulation and 
access in both high and low income countries. What is needed in this situation, where values conflict on 
so many levels, is greater clarity about the threshold at which the well-being of patients and societal 
health should outweigh corporate interests. To achieve this clarity, we need far greater transparency 
around why medicines cost the amount they do. In cases where large populations of patients are denied 
access to life changing medicines because of prices that cannot be justified, we need to have legal 
frameworks and mechanisms in place that allow patients to access these treatments (on a large scale if 
necessary) from elsewhere without fear of personal or societal repercussions. Where current legislation 
and regulation does not permit affordable access to life saving treatments, governments need the 
political will to take action and change legislation. When mechanisms exist within current legal 
frameworks for accessing medicines, governments need to leverage them. In short, we need to replace 
amoral market-logic with fair-mindedness and compassionate rationality. 
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